NAV

Gemcitabine elaidate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Gemcitabine elaidate
DrugBank Accession Number
DB12564
Background

Gemcitabine elaidate has been used in trials studying the treatment of Solid Tumor, Lung Cancer, Non-small-cell Lung Cancer, and Metastatic Pancreatic Adenocarcinoma.

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 527.654
Monoisotopic: 527.317077823
Chemical Formula
C27H43F2N3O5
Synonyms
  • 2'-Deoxy-2',2'-difluorocytidine 5'-(9E)-octadec-9-enoate
  • 5'-O-(TRANS-9''-OCTADECENOYL)-1-.BETA.-D-2'DEOXY-2',2'-DIFLUOROCYTIDINE
  • 5'-O-(trans-9"-octadecenoyl)-1-beta-D-2'deoxy-2',2'-difluorocytidine
  • Gemcitabine elaidate
External IDs
  • CO-1.01
  • CO-101
  • CP-4126
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleosides. These are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Pyrimidine nucleosides
Sub Class
Pyrimidine 2'-deoxyribonucleosides
Direct Parent
Pyrimidine 2'-deoxyribonucleosides
Alternative Parents
Aminopyrimidines and derivatives / Pyrimidones / Fatty acid esters / Hydropyrimidines / Imidolactams / Oxolanes / Heteroaromatic compounds / Amino acids and derivatives / Secondary alcohols / Carboxylic acid esters
show 10 more
Substituents
Alcohol / Alkyl fluoride / Alkyl halide / Amine / Amino acid or derivatives / Aminopyrimidine / Aromatic heteromonocyclic compound / Azacycle / Carbonyl group / Carboxylic acid derivative
show 25 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
231C73W7LG
CAS number
210829-30-4
InChI Key
HESSNRGIEVBPRB-QDDPNBLJSA-N
InChI
InChI=1S/C27H43F2N3O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(33)36-20-21-24(34)27(28,29)25(37-21)32-19-18-22(30)31-26(32)35/h9-10,18-19,21,24-25,34H,2-8,11-17,20H2,1H3,(H2,30,31,35)/b10-9+/t21-,24-,25-/m1/s1
IUPAC Name
[(2R,3R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-4,4-difluoro-3-hydroxyoxolan-2-yl]methyl (9E)-octadec-9-enoate
SMILES
CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O

References

General References
Not Available
PubChem Compound
9828310
PubChem Substance
347828787
ChemSpider
8004050
ChEBI
177710
ChEMBL
CHEMBL3039516
ZINC
ZINC000014208575

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAdvanced Adenocarcinoma of Pancreas1
2CompletedTreatmentPancreatic Adenocarcinoma Metastatic2
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentSolid Tumors1
1TerminatedTreatmentLung Cancer / Non-Small Cell Lung Cancer (NSCLC) / Solid Tumors1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00035 mg/mLALOGPS
logP6.37ALOGPS
logP5.98Chemaxon
logS-6.2ALOGPS
pKa (Strongest Acidic)11.52Chemaxon
pKa (Strongest Basic)-0.96Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area114.45 Å2Chemaxon
Rotatable Bond Count19Chemaxon
Refractivity137.16 m3·mol-1Chemaxon
Polarizability58.29 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-002f-9112220000-82cdaee0208bb46f2a6b
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0030090000-6ae16713af508acff2e3
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-0020900000-ef66c7454f47933e7416
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03xu-9600100000-118b07714f8cb9946835
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-8280900000-0c4f0ac589f4eafcf73f
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-000x-9710000000-256b09936c0772c43b33
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-219.51411
predicted
DeepCCS 1.0 (2019)
[M+H]+221.84456
predicted
DeepCCS 1.0 (2019)
[M+Na]+227.68153
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 22:54 / Updated at July 18, 2023 22:57